Crispr glaucoma gene therapy

CRISPR glaucoma gene therapy

CRISPR glaucoma gene therapy is an experimental approach that uses a gene-editing tool called CRISPR to change DNA in eye cells with the goal of preventing or treating pressure-related vision loss. The idea is to fix or silence faulty genes that contribute to fluid buildup, protect the nerve cells that carry vision, or improve the eye’s natural drainage system so pressure stays lower. Because the eye is small and relatively closed off from the rest of the body, it is a promising place for targeted genetic treatments that might need only a single procedure. Scientists deliver the gene-editing system into the eye using safe carriers, and in early research they have been able to reduce harmful protein buildup and protect nerve cells in animals. The potential benefits are big: a long-lasting or permanent treatment instead of daily eye drops, and therapies tailored to a person’s specific genetic risk. But there are real risks to study carefully, such as accidental edits in the wrong place, immune reactions, and the need to make sure changes are safe over many years. Right now this approach is mostly in labs or early clinical trials, so it is not a routine treatment yet. Ongoing research aims to prove it is both effective and safe before it becomes widely available, and doctors are watching results closely because successful gene therapy could transform how the disease is managed.